D. Conception, D. Laurent-puig, J. Pekin, D. R. Olson, J. B. Link et al., Acquisition of data (provided animals, acquired and managed patients, provided facilities, Taly Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): P. Laurent-Puig

D. Tougeron, T. Lecomte, J. C. Pages, C. Villalva, C. Collin et al., Effect of low-frequency KRAS mutations on the response to anti-EGFR therapy in metastatic colorectal cancer, Ann Oncol, vol.24, pp.1267-73, 2013.

A. Jemal, F. Bray, M. M. Center, J. Ferlay, E. Ward et al., Global cancer statistics, CA Cancer J Clin, vol.61, pp.69-90, 2011.

A. Lievre, J. B. Bachet, V. Boige, A. Cayre, L. Corre et al., KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab, J Clin Oncol, vol.26, pp.374-383, 2008.
URL : https://hal.archives-ouvertes.fr/hal-00363737

S. Khambata-ford, C. R. Garrett, N. J. Meropol, M. Basik, C. T. Harbison et al., Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab, J Clin Oncol, vol.25, pp.3230-3237, 2007.

D. Fiore, F. Blanchard, F. Charbonnier, F. , L. Pessot et al., Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy, Br J Cancer, vol.96, pp.1166-1175, 2007.

W. De-roock, H. Piessevaux, D. Schutter, J. Janssens, M. et al., KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab, Ann Oncol, vol.19, pp.508-523, 2008.

H. Linardou, I. J. Dahabreh, D. Kanaloupiti, F. Siannis, D. Bafaloukos et al., Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer, Lancet Oncol, vol.9, pp.962-72, 2008.

P. Laurent-puig, A. Cayre, G. Manceau, E. Buc, J. B. Bachet et al., Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer, J Clin Oncol, vol.27, pp.5924-5954, 2009.
URL : https://hal.archives-ouvertes.fr/hal-00618089

A. Custodio and J. Feliu, Prognostic and predictive biomarkers for epidermal growth factor receptor-targeted therapy in colorectal cancer: beyond KRAS mutations, Crit Rev Oncol Hematol, vol.85, pp.45-81, 2013.

J. Y. Douillard, K. S. Oliner, S. Siena, J. Tabernero, R. Burkes et al., Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer, N Engl J Med, vol.369, pp.1023-1057, 2013.

L. A. Diaz, R. T. Williams, J. Wu, I. Kinde, J. R. Hecht et al., The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers, Nature, vol.486, pp.537-577, 2012.

S. Oltedal, O. G. Aasprong, J. H. Moller, H. Korner, B. Gilje et al., Heterogeneous distribution of K-ras mutations in primary colon carcinomas: implications for EGFR-directed therapy, Int J Colorectal Dis, vol.26, pp.1271-1278, 2011.

J. H. Van-krieken, J. A. Kirchner, T. Carneiro, F. Seruca, R. Bosman et al., KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program, Virchows Arch, vol.453, pp.417-448, 2008.

P. Carotenuto, C. Roma, A. M. Rachiglio, F. Tatangelo, C. Pinto et al., Detection of KRAS mutations in colorectal carcinoma patients with an integrated PCR/sequencing and real-time PCR approach, Pharmacogenomics, vol.11, pp.1169-79, 2010.

S. Dufort, M. J. Richard, and F. De-fraipont, Pyrosequencing method to detect KRAS mutation in formalin-fixed and paraffin-embedded tumor tissues, Anal Biochem, vol.391, pp.166-174, 2009.

S. Ogino, T. Kawasaki, M. Brahmandam, L. Yan, M. Cantor et al., Sensitive sequencing method for KRAS mutation detection by pyrosequencing, J Mol Diagn, vol.7, pp.413-434, 2005.

B. Angulo, E. Garcia-garcia, R. Martinez, A. Suarez-gauthier, E. Conde et al., A commercial real-time PCR kit provides greater sensitivity than direct sequencing to detect KRAS mutations: a morphologybased approach in colorectal carcinoma, J Mol Diagn, vol.12, pp.292-301, 2010.

A. C. Tsiatis, A. Norris-kirby, R. G. Rich, M. J. Hafez, C. D. Gocke et al., Comparison of Sanger sequencing, pyrosequencing, and melting curve analysis for the detection of KRAS mutations: diagnostic and clinical implications, J Mol Diagn, vol.12, pp.425-457, 2010.

V. Taly, D. Pekin, A. E. Abed, and P. Laurent-puig, Detecting biomarkers with microdroplet technology, Trends Mol Med, vol.18, pp.405-421, 2012.
URL : https://hal.archives-ouvertes.fr/inserm-02299585

D. Pekin, Y. Skhiri, J. C. Baret, L. Corre, D. Mazutis et al., Quantitative and sensitive detection of rare mutations using droplet-based microfluidics, Lab Chip, pp.2156-66, 2011.
URL : https://hal.archives-ouvertes.fr/hal-02148770

L. Pinheiro, K. R. Emslie, B. J. Hindson, C. Hindson, J. Herrmann et al., Evaluation of a droplet digital polymerase chain reaction format for DNA copy number quantification, Anal Chem, vol.84, pp.1003-1014, 2012.

B. J. Hindson, K. D. Ness, D. A. Masquelier, P. Belgrader, N. J. Heredia et al., High-throughput droplet digital PCR system for absolute quantitation of DNA copy number, Anal Chem, vol.83, pp.8604-8614, 2011.

A. C. Hatch, J. S. Fisher, A. R. Tovar, A. T. Hsieh, R. Lin et al., 1-Million droplet array with wide-field fluorescence imaging for digital PCR, Lab Chip, vol.11, pp.3838-3883, 2011.

Q. Zhong, S. Bhattacharya, S. Kotsopoulos, J. Olson, V. Taly et al., Multiplex digital PCR: breaking the one target per color barrier of quantitative PCR, Lab Chip, vol.11, pp.2167-74, 2011.
URL : https://hal.archives-ouvertes.fr/inserm-02299588

A. Didelot, S. K. Kotsopoulos, A. Lupo, D. Pekin, X. Li et al., Multiplex picoliter-droplet digital PCR for quantitative assessment of DNA integrity in clinical samples, Clin Chem, vol.59, pp.815-838, 2013.
URL : https://hal.archives-ouvertes.fr/inserm-02299583

V. Taly, D. Pekin, L. Benhaim, S. K. Kotsopoulos, L. Corre et al., Multiplex picodroplet digital PCR to detect KRAS mutations in circulating DNA from the plasma of colorectal cancer patients, Clin Chem, vol.59, pp.1722-1753, 2013.
URL : https://hal.archives-ouvertes.fr/inserm-02299581

S. Misale, R. Yaeger, S. Hobor, E. Scala, M. Janakiraman et al., Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer, Nature, vol.486, pp.532-538, 2012.

D. Fiore, F. , L. Pessot, F. Blanchard, F. Charbonnier et al., Clinical relevance of kras mutation detection in metastatic colorectal cancer treated by cetuximala plus chemotherapy, Gastroenterology, vol.132, p.433, 2007.

F. Molinari, L. Felicioni, M. Buscarino, D. Dosso, S. Buttitta et al., Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer, Clin Cancer Res, vol.17, pp.4901-4915, 2011.

H. Bando, T. Yoshino, K. Tsuchihara, N. Ogasawara, N. Fuse et al., KRAS mutations detected by the amplification refractory mutation systemScorpion assays strongly correlate with therapeutic effect of cetuximab, Br J Cancer, vol.105, pp.403-409, 2011.

F. Diehl, M. Li, D. Dressman, Y. He, D. Shen et al., Detection and quantification of mutations in the plasma of patients with colorectal tumors, Proc Natl Acad Sci U S A, vol.102, pp.16368-73, 2005.

F. Diehl, K. Schmidt, K. H. Durkee, K. J. Moore, S. N. Goodman et al., Analysis of mutations in DNA isolated from plasma and stool of colorectal cancer patients, Gastroenterology, vol.135, pp.489-98, 2008.

N. J. Heredia, P. Belgrader, S. Wang, R. Koehler, J. Regan et al., Droplet Digital PCR quantitation of HER2 expression in FFPE breast cancer samples, Methods, vol.59, pp.20-23, 2013.

F. Diehl and L. A. Diaz, Digital quantification of mutant DNA in cancer patients, Curr Opin Oncol, vol.19, pp.36-42, 2007.

B. Vogelstein, K. W. Kinzler, and P. Digital, Proc Natl Acad Sci U S A, vol.96, pp.9236-9277, 1999.

E. Crowley, D. Nicolantonio, F. Loupakis, F. Bardelli, and A. , Liquid biopsy: monitoring cancer-genetics in the blood, Nat Rev Clin Oncol, vol.10, pp.472-84, 2013.

E. Bellon, M. J. Ligtenberg, S. Tejpar, K. Cox, G. De-hertogh et al., External quality assessment for KRAS testing is needed: setup of a European program and report of the first joined regional quality assessment rounds, Oncologist, vol.16, pp.467-78, 2011.

P. Diehl, Molecular analysis of tumors to improve characterization and treatment, Clin Cancer Res, vol.21, pp.1087-1097, 2013.